Season 2 (2021-2030)

Metabolic - Antibody (1)

Modality Indication Targets Stage Company Project No. Detail
1 A Study on the Hit to Lead Optimization of Resistin Targeting Antibodies as a Treatment for Non-Alcoholic Fatty Liver Disease
Antibody NASH Resistin, CAP1 Lead Seoul National University Hospital HN21C0524
BACK